Researchers discover path to blocking fatal toxins

A team of researchers at the Hebrew University of Jerusalem says it has found a way to block a group of fatal bacterial toxins that have to date resisted all attempts to arrest them through the use of conventional drugs.

These toxins, called superantigens, are produced by a group of "violent" staphylococcal and streptococcal bacteria. When these bacteria attack humans, they set off an extreme described as an "immune storm," that is, an of a magnitude higher in intensity than during a regular immune reaction. The result is often fatal toxic or brought on by the excessive immune response.

Working to develop the first effective antidote under funding from the of the US Department of Defense and the US National Institutes of Health, the laboratory headed by Prof. Raymond Kaempfer of the Institute for Medical Research Israel Canada (IMRIC) at the Hebrew University Faculty of Medicine, has studied how superantigen toxins engage the immune system. The researchers discovered that in order to exert its harmful action, a superantigen must first bind to a protein on the surface of the human immune cell, a receptor called CD28.

CD28 has been known for a long time as a key participant in every immune response, but its ability to recognize microbial components -- the superantigens -- came as a complete surprise. The Kaempfer team discovered that superantigens do their lethal work by co-opting CD28 as their receptor, and that binding of a superantigen to CD28 is the key in the pathway to an immune storm.

They mapped the regions where the superantigen and CD28 contact each other and found that to induce an immune storm, superantigens must bind specifically into that part of the CD28 molecule where, normally, it pairs with another CD28 molecule.

Using that insight, they next designed decoys, short that mimic the contact domain in the superantigen or in CD28. Such decoys, they could show, act as a monkey wrench that blocks the engagement of CD28 receptor by the superantigen toxin, thereby inhibiting the overly strong immune response and protecting animals from the toxic consequences, including from death.

All the superantigen toxins function via the same CD28 receptor, rendering the decoys broadly effective as protective agents. The decoys proved safe in healthy, normal, laboratory animals.

These findings provide a novel therapeutic approach against toxic shock. The decoys are host-oriented therapeutics, directed at the human immune system itself, rather than at the pathogen. Using a host-oriented therapeutic, resistance cannot arise in the infecting bacteria or in the toxins because the decoy targets a human immune receptor that is constant and will not change.

More information: The work of Kaempfer and his team will be published in the PLoS Biology journal on Sept. 13.

Related Stories

Superantigens could be behind several illnesses

Nov 29, 2010

Superantigens, the toxins produced by staphylococcus bacteria, are more complex than previously believed, reveals a team of researchers from the University of Gothenburg in an article published today in the ...

Recommended for you

A better way to track emerging cell therapies using MRIs

5 hours ago

Cellular therapeutics – using intact cells to treat and cure disease – is a hugely promising new approach in medicine but it is hindered by the inability of doctors and scientists to effectively track the movements, destination ...

New biomedical implants accelerate bone healing

12 hours ago

A major success in developing new biomedical implants with the ability to accelerate bone healing has been reported by a group of scientists from the Department of Restorative Dentistry, University of Malaya. ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

nanotech_republika_pl
not rated yet Sep 13, 2011
"All the superantigen toxins function via the same CD28 receptor"

This must be _just one_ type of few mechanisms for superantigen to attack lymphocytes. I understand that superantigens can attach themselves to the T-Cell Receptor (TCR) (not the CD28 receptor).